2026 Annual Meeting | Industry Therapeutic Update from Eli Lilly and Company: Connecting Minds: A real-world look at how neurology and primary care can collaborate to improve Alzheimer's disease care

Date Monday 04/20/26

Time 11:45 AM - 12:45 PM CDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Join us for a robust discussion between experts as they share their real-world experience working together to develop an enhanced care pathway for patients with Alzheimer’s disease (AD). This moderated conversation will delve into their successful collaboration to overcome barriers and improve patient care, highlighting key provider touchpoints across the AD continuum, detailing roles and responsibilities across the care team, and providing strategies that can be adapted and implemented in practice.

CME Available No CME available

Event Timeline
11:45 AM - 12:45 PM CDT	Speaker	TBD

Faculty Disclosures
Jeffrey M. Burns, MD	Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Renew Research. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Norris, Keplinger, Hicks and Welder. The institution of Dr. Burns has received research support from National Institutes of Health. The institution of Dr. Burns has received research support from Biogen. The institution of Dr. Burns has received research support from Eli Lilly. The institution of Dr. Burns has received research support from Amylyx. The institution of Dr. Burns has received research support from Abbvie. The institution of Dr. Burns has received research support from Astra-Zeneca.
Jennifer Woodward, MD	Dr. Woodward has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Woodward has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk.

��ɫ��

��ɫ��